NEW YORK, May 14, 2019 (GLOBE NEWSWIRE) --
AXIMÂ® Biotechnologies, Inc. (AXIM)
(âAXIMÂ® Biotechâ, âAximâ, or the âCompanyâ), a world leader in
cannabinoid research and development, today announced that the
Company will be attending and presenting at Cannastocks 2019 Q1
Conference, taking place in New York on May 15, 2019.
AXIMâs Chief Executive Officer John W. Huemoeller
II will bring his expertise to this yearâs event, presenting on the
Companyâs updated business strategy, proprietary controlled-release
technology and patent on all chewing gum containing cannabinoids,
including the Companyâs patented flagship chewing gum products. His
presentation is scheduled to take place from 4:00 p.m. to 4:25 p.m.
ET. The presentation will be available online to non-attendees as
well for up to 90 days following.
âI look forward to introducing Cannastocks 2019
Q1 attendees to AXIMâs updated business strategy and educating them
on what sets AXIM apart in cannabis research and development,â
Huemoeller said. âThe company has recently made a lot of
advancements and updated its pipeline to reflect our shift in
business goals while maintaining our reputation as an industry
AXIMÂ® Biotech will be one of eight publicly
traded companies presenting at the conference. Mr. Huemoeller will
also be available for one-on-one meetings for those interested in
learning more about AXIM while at the conference.
The Cannastocks 2019 Q1 Conference is a
live-stream investor conference. The event will feature
presentations by public companies, providing insight on innovation,
consolidation, international expansion and specialization in the
fast-growing cannabis industry.
A copy of AXIMâs management presentation can be
found at: https://ir.aximbiotech.com/presentations.
For more information about the event, please
To learn more about AXIMÂ®
Biotechnologies, Inc., please visit http://aximbiotech.com/.
About AXIMÂ® Biotechnologies
AXIMÂ® Biotechnologies, Inc. (AXIM) is a world leader in the
research and development of cannabinoid-based pharmaceutical and
nutraceutical products. Along with building a robust intellectual
property portfolio, AXIM is focused on clinical development
programs that bring more efficacy and/or lower side effects than
existing alternatives and require small to medium budgets and
timelines to bring to market which presents a high added-value to
the pharmaceutical field.
AXIM's flagship products include MedChewÂ® with
dronabinol, which is planned to undergo a bioequivalence study to
fast track through FDA as an alternative to approved Marinol;
MedChewÂ® RL, which is planned to undergo clinical trials for
treatment of restless leg syndrome; and MedChewÂ® Rx, a combination
cannabidiol (CBD)/tetrahydrocannabinol (THC) functional,
controlled-release chewing gum that is planned to undergo clinical
trials for the treatment of pain and spasticity associated with
Multiple Sclerosis (MS). For more information, please visit
Public Relations Contact:
Chief Executive Officer
Corporate Contact Info:
North American Address:
45 Rockefeller Plaza, 20th Fl.
New York, NY 10111, USA
P. 844 294 6246
Industrieweg 40, Unit B4
3401 MA IJsselstein
This press release may contain certain forward-looking statements
and information, as defined within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934 and is subject to the Safe Harbor created by
those sections. This material contains statements about expected
future events and/or financial results that are forward-looking in
nature and subject to risks and uncertainties. Such forward-looking
statements by definition involve risks, uncertainties and other
factors, which may cause the actual results, performance or
achievements of AXIM Biotechnologies, Inc. to be materially
different from the statements made herein.
AXIMÂ® Biotechnologies does not sell or distribute any products that
are in violation of the United States Controlled Substances Act